Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Signs on Fifth PPO for Coverage of BrevaGen

NEW YORK (GenomeWeb News) – Genetic Technologies today announced an agreement with Three Rivers Provider Network, bringing the total number of covered lives with in-network access to the company's BrevaGen breast cancer test to more than 23 million.

Three Rivers is a supplemental preferred provider organization based in Chula Vista, Calif., and provides healthcare benefits to more than 10 million members at more than 1 million sites across the country.

Today's agreement is the fifth that Melbourne, Australia-based GTG has executed with similar US PPOs, it said. Earlier this week the company reported that its third-quarter revenues narrowed 9 percent year over year. It also announced settlement deals with two companies over lawsuits alleging infringement of a patent held by GTG cover non-coding DNA technology.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.